Health
Should AstraZeneca Be Your Next Coronavirus Buy? – The Motley Fool
The drugmaker might well win the coronavirus vaccine race. What would that mean for its stock?
With no end in sight for the coronavirus pandemic, the world is seeing a frantic effort to develop a vaccine for the deadly virus. SARS-CoV-2, the coronavirus responsible for the COVID-19 disease, has taken close to 833,000 lives worldwide. Global recorded cases stand at 24 million, with 5.8 million — and more than 180,000 COVID-related deaths — in the U.S. alone.
AstraZeneca (NYSE:AZN), based in Cambridge, U.K., is working with the University of Oxford to develop its vaccine candidate, AZD12…
-
Noosa News18 hours agoYoung voices shape Sunshine Coast’s future
-
Business17 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News17 hours agoQueensland government to review greenhouse gas emission reduction targets
-
Noosa News15 hours agoCopperString transmission line projected to cost almost $14b amid massive blowout